Eloxx Pharmaceuticals Completes Acquisition Transaction with Sevion Therapeutics

Company to focus on advancing the clinical development of ELX-02, a disease-modifying therapy for genetic diseases caused by nonsense mutations WALTHAM, Mass., REHOVOT, Israel, and SAN DIEGO, Dec. 22, 2017 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals Ltd. (“Eloxx”) and Sevion Therapeutics, Inc. (OTCQB:SVON) (“Sevion”) today announced the two companies have completed their previously announced acquisition transaction effective as of […]

Read More